| Novartis Pharma Schweiz AG - Simulect 20 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung | | 69542 | | 01 | | Simulect 20 mg | | Pulver zur Herstellung einer Injektions-/Infusionslösung | | L04AC02 | | Basiliximab | | 26.10.2023 | | |
| | Composition | | basiliximabum 20 mg, mannitolum, glycinum, saccharum, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, pro vitro corresp. natrium 0.955 mg. | | Packungsbestandteile | | Dry substance | | | | | | Active Agent | Dose |
|---|
| Basiliximab | 20 mg |
| | | | Inactive agents |
|---|
| Disodium Phosphate | | Glycin | | Potassium Dihydrogenophosphate | | Mannitol | | Sodium Chloride | | Saccharum |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | PR | PR | B | | No |
|
|
